Navigation Links
Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
Date:1/29/2008

- Activity data on lead NNRTI, RDEA806, and next generation compounds to be

discussed -

CARLSBAD, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including RDEA806, RDEA427 and RDEA640, will be presented during the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, February 3-6, 2008.

The presentation details are as follows:

Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

Title: An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent

Activity Profile in the Presence of Human Serum Proteins

Location: Poster Session 123 (Poster # 731) -- Hall A, Hynes Convention

Center

Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

Title: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity

against NNRTI-Resistance Viruses

Location: Poster Session 123 (Poster # 730) -- Hall A, Hynes Convention

Center

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Announces $40 Million Private Placement
2. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences Announces Changes to Research Management
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
7. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
9. YM BioSciences provides update on AeroLEF(TM) clinical development program
10. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Traverse Biosciences announced today that ... development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... TRB-N0224 for the treatment and control of periodontal ... Traverse Biosciences has also granted Aratana an exclusive ... control of periodontal disease in companion animals, inclusive ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Achieved primarily ... produces slides that boast 10 to 100x better detail ... the capabilities of all existing light microscopy methods, it ... micrographs were chosen as the frame of reference because ... , The goal from the earliest discovery days ...
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... NY Researchers from the U.S. Department of Energy,s ... developed a new instrument that allows them to control ... 100 atoms with atomic precision. They created a ... developing the next generation of materials to be used ...
... Allscripts, the leading,provider of clinical software, ... improve healthcare, and the founding member of ... its firm support for the United States ... for physicians to adopt,electronic prescribing, or "e-prescribing," ...
... - Appeal of Compensatory Award Will Now Proceed -, ... today that its motion for judgment as a matter of ... of Donna Scroggin v.,Wyeth, in the U.S. District Court, Eastern ... vacates the punitive damages award of,$19,360,000 rendered by the Little ...
Cached Biology Technology:Controlling the size of nanoclusters: First step in making new catalysts 2National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 2National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 3National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 4Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... of Adelaide are a promising step forward in helping ... babies, by reducing the likelihood of adverse inflammatory responses to ... medical procedures experienced by preterm babies, who are often anemic ... Adelaide,s Robinson Institute studied 28 preterm babies (at ...
... is a serious complication of pregnancy and the major cause ... the U.S. It affects about one in 20 pregnancies. The ... urine. The cause of preeclampsia is still unclear. Dr. Florian ... Delbrck Center (MDC) and the Charit), Dr. Ralf Dechend (ECRC ...
... causes of dementia. In Germany and Switzerland alone, around ... doubling of the number of patients worldwide within the ... including amyloid- (Aβ) among others, in patients, brains plays ... from the Department of Neuropathology at Charit and his ...
Cached Biology News:Better blood transfusions for preterm babies 2New risk factor identified for high blood pressure during pregnancy 2New risk factor identified for high blood pressure during pregnancy 3New risk factor identified for high blood pressure during pregnancy 4Alzheimer's disease in mice alleviated promising therapeutic approach for humans 2
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
... [RET-P1] to Rhodopsin Rhodopsin is a ... mammals, birds, amphibians, and reptiles. The rhodopsin ... in the retina. Immunogen: ... Specificity: This antibody specifically labels ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
Biology Products: